A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma
Journal of the American Academy of Dermatology · 2007 · 93 citations · 8 references